ColoCap

ColoCap is a clinical-stage biotechnology company based in Aberdeen, Scotland, specializing in the targeted delivery of drugs to the colon. The company has developed a proprietary pH-sensitive capsule technology that ensures therapeutic agents are released specifically in the lower gastrointestinal tract, bypassing the stomach and small intestine. Its lead product, ColoCap-Aspirin, is a targeted formulation of aspirin designed for the prevention of colorectal cancer. By localizing the release of aspirin in the colon, the company aims to maintain its chemopreventive efficacy while minimizing systemic side effects such as gastric bleeding and ulcers. ColoCap's platform technology has the potential to be applied to a wide range of other medications for gastrointestinal diseases and localized treatments. As a spin-out from the University of Aberdeen, the company leverages academic research to address significant unmet needs in oncology and gastroenterology.